Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys

Brain Res. 1999 Nov 13;847(1):134-8. doi: 10.1016/s0006-8993(99)02015-6.

Abstract

The contribution of the duration of the striatal dopamine (DA) depletion and the expression of parkinsonian signs to changes in D(1) and D(2) receptor number was investigated in the present study. Some animals (N=4) received large doses of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) over short periods of time and were symptomatic for a short period of time (1-3 months; acute parkinsonian group). Other animals (N8 months; chronic parkinsonian group). Despite similar symptomatology and similar degrees of striatal DA denervation, only acute parkinsonian animals had significantly increased numbers of D(1) receptors in most striatal regions. Striatal D(2) receptor binding was elevated in acute parkinsonian monkeys but only in some lateral striatal subregions at mid and caudal levels. These findings further suggest that the duration of parkinsonism is a critical factor in modulating changes in striatal neurochemistry.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Acute Disease
  • Animals
  • Benzazepines / pharmacology
  • Chronic Disease
  • Disease Models, Animal
  • Dopamine Agents / pharmacology
  • Dopamine Antagonists / pharmacology
  • Macaca fascicularis
  • Male
  • Neostriatum / metabolism*
  • Neostriatum / physiopathology
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / physiopathology
  • Radioligand Assay
  • Receptors, Dopamine D1 / metabolism*
  • Receptors, Dopamine D2 / metabolism*

Substances

  • Benzazepines
  • Dopamine Agents
  • Dopamine Antagonists
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine